Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$110.45 USD

110.45
389,055

+0.42 (0.38%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $110.46 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

5 Low Price-to-Book Value Stocks to Buy as 2020 Nears

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals

by Zacks Equity Research

Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kinjel Shah headshot

6 Low Price-to-Book Value Stocks to Buy in December

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com

by Zacks Equity Research

Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com

Sumit Singh headshot

Create a Standout Portfolio With These 4 Low P/CF Stocks

by Sumit Singh

Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.

Jazz (JAZZ) Up 16.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Urmimala Biswas headshot

5 Discounted PEG Stocks for GARP Investors

by Urmimala Biswas

Although PEG is categorized under value investing, it follows the principles of both growth and value investing.

Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

by Zacks Equity Research

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

3 Reasons Growth Investors Will Love Jazz (JAZZ)

by Zacks Equity Research

Jazz (JAZZ) possesses solid growth attributes, which could help it handily outperform the market.

Zacks.com featured highlights include: Jazz Pharmaceuticals, Mr. Cooper Group, Sonic Automotive, Hibbett Sports and Jones Lang LaSalle

by Zacks Equity Research

Zacks.com featured highlights include: Jazz Pharmaceuticals, Mr. Cooper Group, Sonic Automotive, Hibbett Sports and Jones Lang LaSalle

Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%

by Zacks Equity Research

Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Catalyst Focuses on Firdapse Label Expansion Amid Competition

by Zacks Equity Research

Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

Nilanjan Choudhury headshot

Buy These 5 Top-Ranked Stocks With Relative Price Strength

by Nilanjan Choudhury

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio

by Zacks Equity Research

Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.

Jazz Pharmaceuticals plc (JAZZ) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Jazz Pharmaceuticals plc (JAZZ).

Tilray (TLRY) Looks Good: Stock Adds 7.2% in Session

by Zacks Equity Research

Tilray (TLRY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA

by Zacks Equity Research

The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.

Rigel Gets Positive CHMP Review for Thrombocytopenia Drug

by Zacks Equity Research

The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.

Medtronic (MDT) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.

Jazz Pharmaceuticals, Canon, Advanced Energy Industries, Inphi and Skyworks Solutions highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Jazz Pharmaceuticals, Canon, Advanced Energy Industries, Inphi and Skyworks Solutions highlighted as Zacks Bull and Bear of the Day

Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe

by Zacks Equity Research

Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.